Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.70
-0.0300-1.10%
Volume:1.58M
Turnover:4.23M
Market Cap:307.80M
PE:-2.03
High:2.75
Open:2.73
Low:2.62
Close:2.73
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:68.28M
Volume Ratio:0.92
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.95
PE(LYR):-1.93

Loading ...

Perspective Therapeutics (CATX) Receives a Buy from JonesTrading

TIPRANKS
·
May 07

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
May 05

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
May 05

Perspective Therapeutics (CATX) Receives a Buy from Truist Financial

TIPRANKS
·
May 05

Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update

TIPRANKS
·
May 05

Perspective Therapeutics to host analyst event on strategy, enabling technology, pipeline

Reuters
·
Apr 24

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

GlobeNewswire
·
Apr 24

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX)

TIPRANKS
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Maravai Lifesciences Holdings (MRVI) and LENZ Therapeutics (LENZ)

TIPRANKS
·
Apr 20

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 20

Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 20

Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data

TIPRANKS
·
Apr 20

BUZZ-Perspective Therapeutics rises as experimental cancer drug shows promise

Reuters
·
Apr 20

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

TIPRANKS
·
Apr 20

Perspective Therapeutics reports 43% response rate in [212Pb]VMT-α-NET Phase 1/2a trial

Reuters
·
Apr 20

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Aacr Annual Meeting

THOMSON REUTERS
·
Apr 20

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

GlobeNewswire
·
Apr 20

Perspective Therapeutics announces annual shareholder meeting

Reuters
·
Apr 17

Perspective Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Apr 02

Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline

TIPRANKS
·
Apr 02